ArticleInternational journal of women's health2026
The Heterogeneous Global Burden of Hemoglobinopathies Among Women of Childbearing Age, 1990-2021, with Projection to 2030.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically assess the global, regional, and national disease burden of Hemoglobinopathies among women of childbearing age (WCBA) from 1990 to 2021, whilst projecting trends to 2030. Methods: Data were sourced from the Global Burden of Disease 2021 database, covering 204 countries and five socio-demographic index strata. Analyses focused on thalassemia and SCD among WCBA aged 15-49 years, with indicators including prevalence, deaths, and disability-adjusted life years (DALYs). Joinpoint regression, age-period-cohort model, decomposition analysis, frontier analysis, and Bayesian Age-Period-Cohort models explored the changes, drivers, inequalities, and future trends in disease. Results: Between 1990 and 2021, the overall burden of thalassemia in the WCBA declined, with age-standardized prevalence rates (ASPR) decreasing from 12.75 to 9.90 per 100,000 population and age-standardized DALY rates falling from 9.69 to 6.56 per 100,000 population. Conversely, SCD showed a marked increase: ASPR rose from 42.99 to 67.17, age-standardized death rates (ASDR) increased from 0.35 to 0.54, and age-standardized DALY rates climbed from 25.88 to 40.76 per 100,000 population. Regional and national disparities were pronounced, with thalassemia bearing the highest burden in East Asia, while SCD predominantly concentrated in sub-Saharan Africa with low SDI. Decomposition analysis indicated that the decline in thalassemia primarily stemmed from epidemiological improvements, whereas the rise in SCD was mainly associated with population growth and inadequate healthcare accessibility. Projections suggest that by 2030, the burden of thalassemia will continue to decrease, while SCD will further intensify. Conclusion: Thalassemia and SCD exhibit divergent disease burden trends within the WCBA, posing significant challenges to maternal health. Future efforts should focus on expanding tailored premarital and prenatal screening, genetic counselling, and multidisciplinary antenatal management to reduce inequalities and achieve sustained reductions in haemoglobinopathy burden, particularly in low-SDI regions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.